Floatz logo

Hydroxyurea

Sickle Cell-beta-thalassemia

Nova Laboratories LimitedSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Sickle Cell-beta-thalassemia cohort.

Asset / SponsorPhaseRating
ALLOGENEIC, EX VIVO EXPANDED, UMBILICAL CORD BLOOD-DERIVED HEMATOPOIETIC CD133+ PROGENITOR CELLS- CULTURED FRACTION (CF)
Gamida Cell ltd
Phase 1/2CCC
Peripheral Blood Stem Cell Graft That Are Cd34+ Selected
Catherine Bollard
Phase 1CC
Bortezomib
M.D. Anderson Cancer Center
Early Phase 1C
Busulphan
M.D. Anderson Cancer Center
Early Phase 1C
DEXAMETHASONE
M.D. Anderson Cancer Center
Early Phase 1C

View all 10 →

Same molecule, other indications

Hydroxyurea is also rated in:

beta-thalassemia majorDormant
BBB
Indicative ·
77 / 100
View asset →
sickle cell diseaseDormant
BB
Indicative ·
71 / 100
View asset →
thalassemiaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →